Vaccines are considered as one of the most effective methods for the prevention and control of infectious diseases. This is primarily due to their ability to target specific pathogens and stimulate the immune system. Moreover, these products are also inexpensive and can be used to treat multiple diseases simultaneously.
The global intramuscular vaccine adjuvants market is expected to experience substantial growth during the forecast period due to several factors. These include an increased demand for safe and effective vaccines, the ongoing pace of innovation in this field, and financial support from various private and public sector investors. A growing geriatric population coupled with increasing prevalence of chronic diseases are other major drivers fuelling growth of the global vaccine adjuvants market. Moreover, the presence of large numbers of hospitals and other healthcare facilities is also expected to propel market growth during the forecast period. In addition, the emergence of novel therapeutics is further expected to boost market growth.
On the other hand, side-effects and toxicity of adjuvants is expected to hinder the market growth.
- This report provides in-depth analysis of the global intramuscular vaccine adjuvants market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global intramuscular vaccine adjuvants market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, and OZ Biosciences.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global intramuscular vaccine adjuvants market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global intramuscular vaccine adjuvants market.
-
- Oil-based Adjuvants
- Liposome-based Adjuvants
- Polymer-based Adjuvants
- Mineral-based Adjuvants
- Others
-
- Pediatrics
- Adults
- Geriatrics
-
- Infectious diseases
- Cancer
- Others
-
- Hospitals
- Clinics
- Research Centers
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Novavax, Inc.
- Adjuvance Technologies, Inc.
- Invivogen
- Vaxine Pty Ltd.
- SEPPIC
- SPI Pharma, Inc.
- Agenus Inc.
- Avanti Polar Lipids, Inc.
- CSL Limited
- OZ Biosciences
